Eliogreg
@eliogreg.bsky.social
MD, Medical Oncologist @ospNiguarda #LCSM #ThoracicOncology
Always find a way to have fun!
Always find a way to have fun!
MISSIONE INTERNAZIONALE – SALPIAMO PER GAZA chuffed.org/project/1406...
MISSIONE INTERNAZIONALE – SALPIAMO PER GAZA
MISSIONE INTERNAZIONALE – SALPIAMO PER GAZAMentre il genocidio in corso a Gaza peggiora di giorno in giorno e le istituzioni restano in silenzio, persone da tutto il mondo si stanno mobilitando per co...
chuffed.org
August 14, 2025 at 12:20 PM
MISSIONE INTERNAZIONALE – SALPIAMO PER GAZA chuffed.org/project/1406...
A new standard of care for mEGFR #NSCLC. #MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, 3yr 60% vs 51%, going even better over time) vs #osimertinib.
More effort is needed to manage toxicity.
#ELCC2025
More effort is needed to manage toxicity.
#ELCC2025
March 26, 2025 at 7:18 PM
A new standard of care for mEGFR #NSCLC. #MARIPOSA (Ami + Lazer) shows significant OS (HR 0.75, 3yr 60% vs 51%, going even better over time) vs #osimertinib.
More effort is needed to manage toxicity.
#ELCC2025
More effort is needed to manage toxicity.
#ELCC2025
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) - Journal of Thoracic Oncology www.jto.org/article/S155...
March 10, 2025 at 3:43 PM
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON) - Journal of Thoracic Oncology www.jto.org/article/S155...
#Ivonescimab versus #pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
March 8, 2025 at 8:33 PM
#Ivonescimab versus #pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
PFS≥12 on #durvalumab might be a positive predictive factor for ICB re-treatment
#nsclc #lcsm
www.ejcancer.com/article/S095...
#nsclc #lcsm
www.ejcancer.com/article/S095...
Comparative Efficacy of Immunotherapy-based treatment versus Chemotherapy-only in Patients with Unresectable NSCLC with Disease Progression Post Chemoradiation and Durvalumab
The current standard of care for fit patients with unresectable stage III NSCLC involves
concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs
in approximately 2/3 of patie...
www.ejcancer.com
February 13, 2025 at 8:46 PM
PFS≥12 on #durvalumab might be a positive predictive factor for ICB re-treatment
#nsclc #lcsm
www.ejcancer.com/article/S095...
#nsclc #lcsm
www.ejcancer.com/article/S095...
Reposted by Eliogreg
🔥Annals of Oncology🆙
✅Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?
🎯Performing biopsies at treatment resistance is crucial to aid drug development
👥Drs. Jordi Remon and Stephanie Saw
#LCSM @oncoalert.bsky.social #EGFR
www.annalsofoncology.org/article/S092...
✅Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?
🎯Performing biopsies at treatment resistance is crucial to aid drug development
👥Drs. Jordi Remon and Stephanie Saw
#LCSM @oncoalert.bsky.social #EGFR
www.annalsofoncology.org/article/S092...
January 24, 2025 at 2:47 PM
🔥Annals of Oncology🆙
✅Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?
🎯Performing biopsies at treatment resistance is crucial to aid drug development
👥Drs. Jordi Remon and Stephanie Saw
#LCSM @oncoalert.bsky.social #EGFR
www.annalsofoncology.org/article/S092...
✅Teliso-V and osimertinib: the METamorphosis of EGFR-mutant lung cancer?
🎯Performing biopsies at treatment resistance is crucial to aid drug development
👥Drs. Jordi Remon and Stephanie Saw
#LCSM @oncoalert.bsky.social #EGFR
www.annalsofoncology.org/article/S092...
Reposted by Eliogreg
Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.
www.jnj.com/media-center...
www.jnj.com/media-center...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
www.jnj.com
January 7, 2025 at 1:34 PM
Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.
www.jnj.com/media-center...
www.jnj.com/media-center...
How to reduce skin toxicity from #amivantamab #lazertinib in #NSCLC?
📝 oral antibiotic (doxycycline or minocycline) twice daily for 12 weeks 💊, then topical antibiotic (clindamycin 1 percent), antibacterial wash (chlorhexidine 4 percent), and daily ceramides-based noncomedogenic moisturizer 🧴
📝 oral antibiotic (doxycycline or minocycline) twice daily for 12 weeks 💊, then topical antibiotic (clindamycin 1 percent), antibacterial wash (chlorhexidine 4 percent), and daily ceramides-based noncomedogenic moisturizer 🧴
COCOON study meets primary endpoint demonstrating statistically significant and clinically meaningful reduction in dermatologic reactions with easy-to-use prophylactic regimen for patients with EGFR-m...
innovativemedicine.jnj.com
January 15, 2025 at 8:08 AM
How to reduce skin toxicity from #amivantamab #lazertinib in #NSCLC?
📝 oral antibiotic (doxycycline or minocycline) twice daily for 12 weeks 💊, then topical antibiotic (clindamycin 1 percent), antibacterial wash (chlorhexidine 4 percent), and daily ceramides-based noncomedogenic moisturizer 🧴
📝 oral antibiotic (doxycycline or minocycline) twice daily for 12 weeks 💊, then topical antibiotic (clindamycin 1 percent), antibacterial wash (chlorhexidine 4 percent), and daily ceramides-based noncomedogenic moisturizer 🧴
A cancer was detected in 48.6% of participants who initially received nonreportable or unusual #prenatal #cfDNA-sequencing results
Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer | NEJM
Cell-free DNA (cfDNA) sequence analysis to screen for fetal aneuploidy can incidentally
detect maternal cancer. Additional data are needed to identify DNA-sequencing patterns
and other biomarkers t...
www.nejm.org
December 8, 2024 at 2:55 PM
A cancer was detected in 48.6% of participants who initially received nonreportable or unusual #prenatal #cfDNA-sequencing results
Final survival from phase II study of #lorlatinib in #ALK #NSCLC. In treatment naive (n=30), 5y OS 76%
www.jto.org/article/S155...
www.jto.org/article/S155...
Brief Report: Final overall survival and long-term safety of lorlatinib in patients with ALK-positive non-small cell lung cancer from the pivotal phase 2 study
Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic
lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance
mutations. We present overall su...
www.jto.org
November 24, 2024 at 9:56 PM
Final survival from phase II study of #lorlatinib in #ALK #NSCLC. In treatment naive (n=30), 5y OS 76%
www.jto.org/article/S155...
www.jto.org/article/S155...
#ARTICUNO study
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit
#LCSM
www.sciencedirect.com/science/arti...
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit
#LCSM
www.sciencedirect.com/science/arti...
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth fact…
www.sciencedirect.com
November 20, 2024 at 6:38 AM
#ARTICUNO study
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit
#LCSM
www.sciencedirect.com/science/arti...
📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib
🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms
🔎 #E709 mut->lack of benefit
#LCSM
www.sciencedirect.com/science/arti...